James C. Fuscoe Data-verified
Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.
Researcher
faculty
Research Areas
Links
Biography and Research Information
OverviewAI-generated summary
James C. Fuscoe's research focuses on understanding and mitigating the cardiotoxic effects of chemotherapy, particularly doxorubicin. His work investigates the molecular mechanisms underlying doxorubicin-induced cardiotoxicity, including the role of specific pathways like the apelin-APJ system and microRNAs such as miR-34a-5p. Fuscoe has explored sex-related differential cardiotoxicity in mice and identified potential circulating biomarkers for early detection of chronic cardiotoxicity.
His research also extends to identifying predictive risk factors for myocardial injury in children undergoing anthracycline treatment. Fuscoe's publication record includes studies on gene expression profiling, oligonucleotide array sequence analysis, and the effects of xenobiotics in animal models, including mice and rats. He has a substantial publication count of 165 and an h-index of 47, with over 13,000 citations, indicating significant impact in his field. Fuscoe collaborates with researchers at the National Center for Toxicological Research and the University of Arkansas for Medical Sciences.
His work utilizes various techniques to assess toxicity and identify therapeutic targets. By examining genetic and molecular responses in preclinical models, Fuscoe aims to improve the safety of cancer treatments and enhance patient outcomes, particularly for vulnerable populations like children undergoing chemotherapy.
Metrics
- h-index: 47
- Publications: 168
- Citations: 13,441
Selected Publications
-
Correction: Exploring Predictive Risk Factors for Myocardial Injury in Children Treated with Anthracyclines: A Pilot Study (2026)
-
Exploring Predictive Risk Factors for Myocardial Injury in Children Treated with Anthracyclines: A Pilot Study (2025)
-
Potential role of the apelin‐APJ pathway in sex‐related differential cardiotoxicity induced by doxorubicin in mice (2022)
-
MicroRNA‐34a‐5p as a promising early circulating preclinical biomarker of doxorubicin‐induced chronic cardiotoxicity (2022)
-
Doxorubicin‐induced delayed‐onset subclinical cardiotoxicity in mice (2021)
Collaboration Network
Top Collaborators
- Doxorubicin‐induced delayed‐onset subclinical cardiotoxicity in mice
- MicroRNA‐34a‐5p as a promising early circulating preclinical biomarker of doxorubicin‐induced chronic cardiotoxicity
- Potential role of the apelin‐APJ pathway in sex‐related differential cardiotoxicity induced by doxorubicin in mice
- Exploring Predictive Risk Factors for Myocardial Injury in Children Treated with Anthracyclines: A Pilot Study
- Doxorubicin‐induced delayed‐onset subclinical cardiotoxicity in mice
- MicroRNA‐34a‐5p as a promising early circulating preclinical biomarker of doxorubicin‐induced chronic cardiotoxicity
- Potential role of the apelin‐APJ pathway in sex‐related differential cardiotoxicity induced by doxorubicin in mice
- Exploring Predictive Risk Factors for Myocardial Injury in Children Treated with Anthracyclines: A Pilot Study
- Doxorubicin‐induced delayed‐onset subclinical cardiotoxicity in mice
- MicroRNA‐34a‐5p as a promising early circulating preclinical biomarker of doxorubicin‐induced chronic cardiotoxicity
- Potential role of the apelin‐APJ pathway in sex‐related differential cardiotoxicity induced by doxorubicin in mice
- Exploring Predictive Risk Factors for Myocardial Injury in Children Treated with Anthracyclines: A Pilot Study
- Doxorubicin‐induced delayed‐onset subclinical cardiotoxicity in mice
- MicroRNA‐34a‐5p as a promising early circulating preclinical biomarker of doxorubicin‐induced chronic cardiotoxicity
- Potential role of the apelin‐APJ pathway in sex‐related differential cardiotoxicity induced by doxorubicin in mice
- Doxorubicin‐induced delayed‐onset subclinical cardiotoxicity in mice
- MicroRNA‐34a‐5p as a promising early circulating preclinical biomarker of doxorubicin‐induced chronic cardiotoxicity
- Potential role of the apelin‐APJ pathway in sex‐related differential cardiotoxicity induced by doxorubicin in mice
- Doxorubicin‐induced delayed‐onset subclinical cardiotoxicity in mice
- MicroRNA‐34a‐5p as a promising early circulating preclinical biomarker of doxorubicin‐induced chronic cardiotoxicity
- Exploring Predictive Risk Factors for Myocardial Injury in Children Treated with Anthracyclines: A Pilot Study
- Doxorubicin‐induced delayed‐onset subclinical cardiotoxicity in mice
- MicroRNA‐34a‐5p as a promising early circulating preclinical biomarker of doxorubicin‐induced chronic cardiotoxicity
- Exploring Predictive Risk Factors for Myocardial Injury in Children Treated with Anthracyclines: A Pilot Study
- Doxorubicin‐induced delayed‐onset subclinical cardiotoxicity in mice
- Doxorubicin‐induced delayed‐onset subclinical cardiotoxicity in mice
- MicroRNA‐34a‐5p as a promising early circulating preclinical biomarker of doxorubicin‐induced chronic cardiotoxicity
- Potential role of the apelin‐APJ pathway in sex‐related differential cardiotoxicity induced by doxorubicin in mice
- Potential role of the apelin‐APJ pathway in sex‐related differential cardiotoxicity induced by doxorubicin in mice
- Potential role of the apelin‐APJ pathway in sex‐related differential cardiotoxicity induced by doxorubicin in mice
- Potential role of the apelin‐APJ pathway in sex‐related differential cardiotoxicity induced by doxorubicin in mice
- Exploring Predictive Risk Factors for Myocardial Injury in Children Treated with Anthracyclines: A Pilot Study
Similar Researchers
Based on overlapping research topics